| Literature DB >> 21606247 |
Masayuki Ishizaki1, Toshihiko Akimoto, Ryuta Muromoto, Mika Yokoyama, Yuya Ohshiro, Yuichi Sekine, Hiroaki Maeda, Kazuya Shimoda, Kenji Oritani, Tadashi Matsuda.
Abstract
Tyrosine kinase-2 (Tyk2), a member of the Jak family of kinases, mediates the signals triggered by various cytokines, including type I IFNs, IL-12, and IL-23. In the current study, we investigated the in vivo involvement of Tyk2 in several IL-12/Th1- and IL-23/Th17-mediated models of experimental diseases, including methylated BSA injection-induced footpad thickness, imiquimod-induced psoriasis-like skin inflammation, and dextran sulfate sodium- or 2,4,6-trinitrobenzene sulfonic acid-induced colitis. In these disease models, Tyk2 deficiency influenced the phenotypes in immunity and/or inflammation. Our findings demonstrate a somewhat broader contribution of Tyk2 to immune systems than previously expected and suggest that Tyk2 may represent an important candidate for drug development by targeting both the IL-12/Th1 and IL-23/Th17 axes.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21606247 DOI: 10.4049/jimmunol.1003244
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422